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Background: Multiple myeloma (MM) is an important human and canine cancer for which novel therapies
remain necessary. VDC-1101 (formerly GS-9219), a novel double prodrug of the anti-proliferative nucleotide analog
9-(2-phosphonylmethoxyethyl) guanine (PMEG), possesses potent cytotoxic activity in vitro in human lymphoblasts
and leukemia cell lines and in vivo in spontaneous canine lymphoma. Given the similarity in lineage between
lymphoma and MM, we hypothesized that VDC-1101 would be active against MM.
Results: We evaluated the in vitro antiproliferative effects of VDC-1101 against 3 human MM cell lines, and we
performed a phase-II clinical trial in 14 dogs with spontaneous MM. Each dog was treated with a maximum of 6
doses of VDC-1101 monotherapy over 10–15 weeks. Dose-dependent antiproliferative activity was observed in all
evaluated cell lines. Major antitumor responses (reduction of serum paraprotein and resolution of hypercalcemia,
peripheral cytopenias and bone marrow plasmacytosis) were observed in 9 of 11 evaluable dogs for a median of
172 days, including a durable stringent complete response (>1047 days) in a dog with melphalan-refractory disease.
2 dogs were euthanized due to presumed pulmonary fibrosis; there were no other dose-limiting toxicities
encountered.
Conclusions: In conclusion, VDC-1101 has significant anti-tumor activity at well-tolerated doses in spontaneous
canine MM.
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An estimated 1 in 165 people will be diagnosed with mul-
tiple myeloma (MM) in their lifetime and 5-year survival
rates are only approximately 34% [1,2]. Despite several re-
cent therapeutic advances, patients with MM still have
significant unmet medical need, especially those who fail
frontline therapy.
VDC-1101, formerly referred to as GS-9219, is a double
prodrug of acyclic nucleotide phosphonate 9-(2-phospho-
nylmethoxyethyl) guanine (PMEG), which was designed* Correspondence: dthamm@colostate.edu
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stated.to preferentially deliver and accumulate PMEG and its
active phosphorylated metabolite, PMEG disphosphate
(PMEGpp) in lymphoid cells while avoiding systemic ex-
posure of PMEG [3]. The delivery of PMEG/PMEGpp
results in cytotoxicity due to inhibition of nuclear DNA
polymerases α, δ and ε [4]. PMEG’s clinical utility is
limited by poor cellular permeability as well as gastro-
intestinal and renal toxicity [5-7]. VDC-1101, however,
is hydrolyzed intracellularly to 9-(2-phosphonylmethox-
yethyl)-N6-cyclopropyl-2,6-diaminopurine (cPrPMEDAP),
deaminated to PMEG and then rapidly converted to
PMEGpp [3]. In normal laboratory dogs, VDC-1101 se-
lectively depletes replicating lymphoid tissues at doses
which spare most other tissues, and demonstrates signifi-
cant antineoplastic activity in dogs with naturally occur-
ring non-Hodgkin’s lymphoma (NHL) [3,8,9]. VDC-1101l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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canine cancer.
The evaluation of novel agents in dogs with naturally
occurring cancers, especially lymphoid neoplasia, can offer
significant insight into an agent’s potential for treatment of
human cancers; dogs have similar responses to standard
chemotherapeutic agents, an intact immune system, and
biologic similarity to humans [10-12]. As in people, canine
MM is initially responsive to chemotherapy; however,
recurrence of drug-resistant disease occurs commonly,
with median survival durations of approximately 18
months following melphalan-based chemotherapy. Long-
term relapse-free survival is exceedingly rare [12-14].
Given the encouraging antitumor activity observed in
dogs with NHL and owing to the similarity in lineage
between B-cell NHL and MM, we sought to determine if
VDC-1101 possessed in vitro antiproliferative activity
against human MM-derived cells and clinical activity in
naturally occurring canine MM.
Results
In vitro antiproliferative effects
VDC-1101 and its bioactive metabolites cPrPMEDAP
and PMEG dose-dependently inhibited growth of H-929,
RPMI-8226 and U-266 human MM cell lines with IC50s
between 0.34 and 0.6 μM. The IC50s observed with
VDC-1101 were roughly the same as those observed
with cPrPMEDAP and PMEG, suggesting that MM cells
possessed the enzymatic machinery necessary to per-
form the hydrolysis and deamination of VDC-1101
(Table 1, Figure 1), and are in keeping with the range of
in vitro IC50 reported for other human hematopoietic
cell lines [3].
In vivo treatment and outcome
Fourteen dogs with MM were enrolled prospectively in
a clinical trial of VDC-1101 monotherapy, which was
administered according to 1 of 3 schedules. Patient and
disease characteristics are reported in Table 2. The 4
pretreated dogs all received and subsequently developed
progressive disease while receiving melphalan and pred-
nisone, and one had additionally failed VAD (vincristine/
doxorubicin/dexamethasone) therapy.
Response to therapy was assessed utilizing an adapta-
tion of the International Uniform Response Criteria forTable 1 Antiproliferative activity of VDC-1101 and its
metabolites in human multiple myeloma cell lines
Calculated IC50 (μM)
H-929 RPMI-8226 U-266
PMEG 1.9 ± 0.6 0.2 ± 0.04 1.0 ± 0.3
cPrPMEDAP 1.8 ± 0.5 0.2 ± 0.06 0.7 ± 0.2
VDC-1101 0.6 ± 0.2 0.34 ± 0.05 0.6 ± 0.2Multiple Myeloma (Table 3) [15]. Three dogs were not
evaluable for response to therapy: 2 dogs were eutha-
nized 1 and 3 days following their first treatment of
VDC-1101 owing to development of acute transverse
myelopathy (1 definitively due to myeloma-associated
vertebral fracture, the other strongly suggested), and 1
dog had light chain disease only and thus paraprotein
was not quantifiable. These three dogs were included in
outcome analysis on an intent-to-treat basis, and their
outcomes treated as events for the purposes of PFI and
ST calculations. Of the remaining 11 dogs, 3 experi-
enced stringent complete responses (sCR) and 6 experi-
enced partial responses (PR), for an overall response
rate of 82%. Serial measurements of paraprotein in the
11 evaluable dogs are depicted in Figure 2, and pre- and
post-treatment bone marrow plasma cell percentages
are provided in Table 4.
Dogs presented with a variety of MM-associated
hematologic and biochemical abnormalities, most of
which resolved or substantially improved in response
to VDC-1101 monotherapy (Table 5). The notable ex-
ception was azotemia, which tended not to improve.
5 dogs were considered censored in the PFI analysis
owing to euthanasia for unrelated reasons (other neopla-
sia, owner request despite PR, pre-existing azotemia un-
responsive to therapy, n = 3), ongoing CR (n = 1) or loss
to follow-up (n = 1). The median follow-up time in cen-
sored patients was 72 days. The median overall PFI was
124 days (1 to >1047 days), and the median PFI in patients
experiencing PR or sCR was 172 days (95 to >1047 days).
The median PFI was not reached in patients experiencing
sCR and 130 days in patients experiencing PR; this differ-
ence was not statistically significant (p = 0.10). There was
no statistical difference in response rate or PFI between
dogs receiving VDC-1101 once every 21 days and those
receiving other schedules (124 vs 172 days, p = 0.46). One
dog was re-treated with VDC-1101 at the time of relapse
(410 days following treatment initiation) and one dog
went on to receive additional specific antineoplastic
therapy following VDC-1101 therapy (prednisone and
melphalan). The overall median ST was 110 days. This
number is less than the median PFI owing to differential
censorship of some patients in PFI and ST calculations.
Of note, 1 dog that had failed previous therapy with
prednisone and melphalan experienced a sCR following
5 treatments with VDC-1101 and was euthanized 1047
days following treatment initiation owing to the develop-
ment of an unrelated neoplasm (apocrine gland carcin-
oma of the anal sac). There was no gross or histologic
evidence of MM on necropsy in this dog. Representative
bone marrow photomicrographs and results of PARR
from this dog are presented in Figure 3. A second dog
remains alive and in sCR >300 days following treatment
initiation.
Figure 1 In vitro antiproliferative effects of VDC-1101 against human multiple myeloma-derived cell lines. Three human myeloma-
derived cell lines were incubated with varying concentrations of drug for 5 days, followed by determination of relative viable cell number using a
luminescent cell viability assay. VDC-1101 demonstrated dose-dependent inhibition of cell growth in all cell lines examined. Error bars
indicate SEM.
Thamm et al. BMC Veterinary Research 2014, 10:30 Page 3 of 7
http://www.biomedcentral.com/1746-6148/10/30Safety and adverse events
Adverse events were transient and self-limiting in most
dogs and are described in Table 6. The single episode of
grade 4 neutropenia occurred after the first dose and was
not accompanied by fever. In this dog, significant neutro-
penia (1000 neutrophils/μL) was present prior to treatment
and normalized with continued therapy. Dermatopathy
was noted in 6 dogs (2 dogs with grade 1 and 4 dogs with
grade 2 severity), and consisted most commonly of focal
mild otitis or pruritic and erythematous skin lesions on the
dorsum. The skin lesions resolved with standard of care
therapy including topical treatments and systemic analge-
sics and antibiotics as needed. A 1-week dose delay was
instituted for one dog for management of dermatopathy.
Two dogs developed severe dyspnea 124 and 135 days fol-
lowing treatment initiation, which led to euthanasia owingTable 2 Patient characteristics
Median age, years (range) 10 (3–14)















Light chain only 1
Not determined 1to respiratory signs. Both of these dogs were experiencing
PRs at the time of euthanasia, and pulmonary fibrosis was
confirmed on necropsy.
Postmortem examinations were performed in 8 dogs.
Extensive infiltration of plasma cells into bone marrow
and parenchymatous organs was demonstrated in 6
dogs. One dog demonstrated hepatic fibrosis and 3 had
renal changes (combinations of renal fibrosis, glomeru-
lopathy, subacute tubular nephrosis, renal infarct, and
chronic interstitial nephritis). The aforementioned dif-
fuse pulmonary fibrosis was noted in 2 dogs, and a third
dog had a focal area of lung fibrosis admixed with ma-
lignant plasma cells.
Discussion
Despite advances and development of novel anti-MM
agents such as immunomodulators, bisphosphonates and
proteasome inhibitors [16], conventional and novel cyto-
toxic agents likely will continue to play an important role
in MM management [17]. VDC-1101, novel prodrug of
the guanine nucleotide analog PMEG, has significant
antitumor activity and acceptable tolerability in dogs
with NHL [3,8,9]. Based on similarities in NHL and
MM lineage and similarities between canine and human
MM, we investigated the activity of VDC-1101 in dogs
with naturally occurring MM.
VDC-1101 exhibited dose-dependent antiproliferative
activity against 3 human MM cell lines, with IC50 values
in the range of those reported against other human
lymphoma and leukemia cell lines, supporting the evalu-
ation of VDC-1101 in dogs with MM. Clear and signifi-
cant antitumor activity was demonstrated with VDC-1101
by clinicopathologic assessment of serum paraproteins,
bone marrow cytology, and a sensitive PCR-based assay
for detecting clonal immunoglobulin gene rearrangement,
as well as normalization or substantial improvement in a
variety of MM-associated clinicopathologic abnormalities.
Notably, a complete and exceptionally durable sCR was
observed in a dog with melphalan-refractory myeloma,





Disappearance of any soft-tissue
plasmacytomas
<5% plasma cells in bone marrow




Same as above, without clonality criterion
Partial Response (PR) >50% reduction in paraprotein from baseline
>50% reduction in bone marrow plasma cells
>50% reduction in soft-tissue plasmacytomas,
if present
Stable Disease (SD) Not meeting criteria for CR, PR or PD
Progressive
Disease (PD)
Increase of 25% from lowest response value in:
Serum paraprotein
Bone marrow plasma cell percentage
(exceeding 10%)
Definite development of new bone or
soft-tissue lesions
Definite increase in size of existing bone or
soft-tissue lesions
Development of hypercalcemia not
attributable to another cause
Table 4 Bone marrow plasma cell percentage before and
after VDC-1101 in 3 dogs experiencing stringent
complete response
Pre-treatment Following final treatment












NB: patient AM’s myeloma diagnosis was made based on hypercalcemia,
monoclonal gammopathy and the presence of multiple bony lytic lesions
on radiographs.
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ond sCR is ongoing at >300 days. Additionally, MM is
generally treated continuously in both dogs and humans.
The fact that durable sCRs have been observed and main-
tained following 5 doses of VDC-1101 without any main-
tenance therapy is likewise encouraging.
The activity observed in both untreated and melphalan-
refractory patients indicates potential utility for VDC-1101
in both induction and rescue chemotherapy settings.Figure 2 Serial measurement of paraprotein over time in 11
dogs with spontaneous myeloma receiving VDC-1101 mono-
therapy. IgA and IgG were measured using radial immunodiffusion.
Normal ranges are 40–160 for IgA and 1000–2000 for IgG. One of
the dogs experiencing SD/PD as best response is not visible on the
graph as pre-treatment IgA concentration was 324 mg/dL.Given the lack of any obvious schedule-dependency on re-
sponse rates or durations, a dosage of 0.82 mg/kg VDC-
1101 free base (1.0 mg/kg succinate salt) as a 30-minute
IV infusion once every 21 days is recommended for
further study.
Acute adverse events were transient and manageable,
and consistent with those described in normal dogs and
in dogs with NHL treated with GS-9219 [3,9]. Severe
pulmonary fibrosis leading to euthanasia was identified
in 2 dogs experiencing PR. This phenomenon has been
observed previously in a small percentage of dogs with
NHL treated with VDC-1101, typically several months
following treatment discontinuation [9]. The observance
of this adverse event in NHL patients led us to pursue con-
current low-dose prednisone therapy in one patient treated
in this study. Future studies will investigate the ability of
concurrent corticosteroids to mitigate this serious adverse
event, and careful monitoring of thoracic radiographs and
assessment for pulmonary signs is warranted.Conclusions
In conclusion, VDC-1101 exhibits substantial activity
against naïve and refractory MM in dogs, with accept-
able toxicity. Pulmonary fibrosis can be observed in
some MM patients treated with VDC-1101, and patients





Anemia 8 2 6
Thrombocytopenia 8 1 7
Hypercalcemia 4 1 3
Azotemia 3
Elevated liver enzymes 2 2
Figure 3 Bone marrow cytologic and molecular complete response in a dog with spontaneous myeloma receiving VDC-1101
monotherapy. The photomicrographs above represent pre-treatment (A) and post-treatment (B) bone marrow cytology from an 8 year old male
castrated Labrador retriever with melphalan-refractory myeloma. The pre-treatment sample contained 30% atypical plasma cells, whereas the
post-treatment sample contained 2% morphologically normal plasma cells. PCR for antigen receptor rearrangement was performed on bone
marrow obtained from this patient prior to and following VDC-1101 (C). 1: Positive control for amplifiable DNA. 2,3: PCR products generated
employing 2 distinct sets of immunoglobulin gene primers. 4: PCR products generated employing primers for T cell receptor gene. A solitary
band, indicating a monoclonal immunoglobulin gene rearrangement, is present in Lane 2 of the pre-treatment sample. This is replaced with
polyclonal immunoglobuin gene rearrangements in Lane 2 of the post-treatment sample, indicating disappearance of the malignant clone.






























*Associated with disease progression in 1 patient.
**Neutropenia existed prior to treatment in this patient.
Thamm et al. BMC Veterinary Research 2014, 10:30 Page 5 of 7
http://www.biomedcentral.com/1746-6148/10/30Methods
In vitro growth inhibition
The U-266, RPMI-8226 and H-929 human MM-derived
cell lines were obtained from ATCC (Manassas, VA). Cell
culture media containing Glutamax was purchased from
Invitrogen (Carlsbad, CA). CellTiter-Glo® was purchased
from Promega (Madison, WI). VDC-1101, cPrPMEDAP
and PMEG were synthesized by Gilead Sciences.
The U-266 cell line was maintained in RPMI-1620
medium supplemented with 15% fetal bovine serum (FBS).
The RPMI-8226 and H-929 cell lines were cultivated in
RPMI-1620 containing 10% FBS. In the case of H-929, 2-
mercaptoethanol with a final concentration of 0.05 mM
was also added. All cells were incubated under standard
conditions (37°C, 5% CO2, humidified).
Cells (67,000 cells/mL) were distributed into 96-well
plates in 150 μL of media/well and incubated overnight.
The following day, 5-fold serial dilutions of the tested
compounds were prepared and the diluted compounds
were added in duplicate in 50 μL/well to the cells. After
a 5-day incubation, 100 μL of cell suspension was re-
moved from each well and cell viability was assed using
a luminescent cell viability assay (CellTiter-Glo®, Pro-
mega, Madison, WI) following manufacturer protocol.
Values were expressed as a percentage of untreated cells
and 50% inhibitory concentration (IC50) values were
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moidal dose response equation.
Patient population
Pet owners presenting to the School of Veterinary Medi-
cine, University of Wisconsin-Madison (UW-SVM) or
the Colorado State University Veterinary Medical Center
(CSU-VMC) were offered study entry for treatment of
their dogs with VDC-1101 under Colorado State Univer-
sity IACUC protocol # 06-100A-03 and University of
Wisconsin IACUC protocol # V01287. Signed informed
consent was obtained from all owners. Prior to entry, dogs
were evaluated by physical examination, complete blood
count (CBC), serum biochemistry profile, urinalysis, thor-
acic radiographs, bone marrow cytology, skeletal survey
radiography, and immunoglobulin quantification by radial
immunodiffusion as described [18]. Concurrent antineo-
plastic therapy was not allowed, with the exception of
low-dose prednisolone (1 mg/kg PO every other day) in a
single dog. Previous cytotoxic chemotherapy was allow-
able with a 3-week washout prior to enrollment.
VDC-1101 Administration protocol
In 4 dogs, VDC-1101 was administered by a 30-minute
intravenous infusion in 5% dextrose for injection (2 mL/
kg) at a dosage of 0.82 mg/kg free base (1.0 mg/kg suc-
cinate salt) on weeks 0 and 1, then 0.66-0.82 mg/kg on
weeks 4, 7, and 10. In 9 dogs, VDC-1101 was adminis-
tered as above at a dosage of 0.82 mg/kg every 3 weeks
for a maximum of 5 treatments. In 1 dog, VDC-1101
was administered at a dosage of 0.25 mg/kg daily for 5
consecutive days, repeated every 21 days for 5 treatment
cycles. The differences in administration protocol were
due to the fact that these 3 schedules of administration
were being evaluated concurrently in dogs with NHL at
the time these patients were treated [9].
Safety evaluation
Adverse events were graded prospectively according to
the Veterinary Cooperative Oncology Group Common
Terminology Criteria for Adverse Events v1.0 [19], based
on client history, physical examination, CBC, biochemis-
try profile, and urinalysis. Evaluations were performed
pretreatment and at all visits thereafter. If dogs experi-
enced grade 3 or greater adverse events, dose reduction
or delay was instituted. Whenever possible, postmortem
examinations were performed at the time of death.
Efficacy evaluation
At each visit including monthly re-checks post-treatment,
owner history, physical examination, CBC, serum bio-
chemistry, urinalysis and immunoglobulin quantification
were performed. Prior to and 1 month following the final
VDC-1101 infusion in dogs experiencing clinical CR, bonemarrow was aspirated for cytology and PCR for antigen re-
ceptor rearrangement (PARR) for clonality assessment.
This was performed as described in 2 cases [20], and using
a modification of the published protocol in 1 case, methods
for which are given in Additional file 1. Response to ther-
apy was assessed utilizing an adaptation of the Inter-
national Uniform Response Criteria for Multiple Myeloma
(Table 3) [15]. The progression-free interval (PFI) was de-
fined as the interval from treatment initiation to develop-
ment of progressive disease. Survival time (ST) was defined
as the interval from treatment initiation until death. Dogs
were censored from analysis if they were in remission at
the time of last treatment, lost to follow-up or died of
disease other than MM. The PFI and ST were calculated
using the Kaplan-Meier product-limit method, which ac-
counts for dogs that were in remission at the time of last
follow-up, lost to follow-up or died of disease other than
MM and are statistically referred to as censored. Outcome
comparisons between groups were made using logrank
analysis. All statistical analyses were performed using a
commercial software package (Prism v6.0, GraphPad Soft-
ware, LaJolla, Ca).
Additional file
Additional file 1: PARR assay methods.
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